Compounds > kahalalide f
Page last updated: 2024-11-11

kahalalide f

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

kahalalide F: a cyclodepsipeptide toxin; isolated from a mollusk, Elysia rubefescens; exhibits antitumoral activity against cell lines of colon cancer and prostatic cancer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44587015
CHEMBL ID499936
MeSH IDM0257257

Synonyms (2)

Synonym
kahalalide f
CHEMBL499936

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Long-term competitive repopulating assays were performed in mice to analyze toxic effects on the hematopoietic stem cells responsible for the multipotential long-term repopulation of hematopoiesis."( In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Albella, B; Bueren, JA; Faircloth, GT; Gómez, SG; Jimeno, J, 2003)		0.32
" Kahalalide F did not show any toxic effect in either short-term or long-term repopulating cells up to 10 microM."( In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Albella, B; Bueren, JA; Faircloth, GT; Gómez, SG; Jimeno, J, 2003)		0.32

Pharmacokinetics

ExcerptReferenceRelevance
" The effect of demographics and/or pathophysiologically relevant factors on KF pharmacokinetic parameters was evaluated."( Population pharmacokinetics of kahalalide F in advanced cancer patients.
Miguel-Lillo, B; Pérez-Ruixo, JJ; Peris-Ribera, JE; Soto-Matos, A; Valenzuela, B, 2015)		0.42
" Within the range of covariates evaluated, age, weight, body surface area, gender, ECOG performance status, presence of liver metastases, creatinine clearance, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, total protein and serum albumin did not contribute to explain KF pharmacokinetic variability to a significant extent."( Population pharmacokinetics of kahalalide F in advanced cancer patients.
Miguel-Lillo, B; Pérez-Ruixo, JJ; Peris-Ribera, JE; Soto-Matos, A; Valenzuela, B, 2015)		0.42
"The integration of pharmacokinetic data from six clinical studies demonstrated KF linear elimination from plasma, dose-proportional exposure and time-independent pharmacokinetics."( Population pharmacokinetics of kahalalide F in advanced cancer patients.
Miguel-Lillo, B; Pérez-Ruixo, JJ; Peris-Ribera, JE; Soto-Matos, A; Valenzuela, B, 2015)		0.42

Dosage Studied

Kahalalide F is pharmaceutically formulated as a lyophilized product containing 150 microg active substance per dosage unit. The pharmaceutical formulation consists of 3 mg citric acid, 3 mg polysorbate 80, and 150 mg of sucrose.

ExcerptRelevanceReference
" The pharmaceutical formulation consists of a lyophilized product containing 150 micrograms kahalalide F, 3 mg citric acid, 3 mg polysorbate 80, and 150 mg of sucrose per dosage unit, to be reconstituted with 3 mL of a mixture composed of Cremophor EL, ethanol, and water (5/5/90% v/v/v), resulting in a solution of pH 3 and to be further diluted in normal saline for infusion."( In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
Beijnen, JH; Bouma, M; Bult, A; Jimeno, JM; Manada, C; Nuijen, B, )		0.13
" Kahalalide F is pharmaceutically formulated as a lyophilized product containing 150 microg active substance per dosage unit."( Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Beijnen, JH; Bouma, M; Bult, A; Jimeno, JM; Lazaro, LL; Manada, C; Nuijen, B, 2001)		0.31
" This dosing route is the intended route of clinical administration."( Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.
Brown, AP; Faircloth, GT; Levine, BS; Morrissey, RL, 2002)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (104)

Assay IDTitleYearJournalArticle
AID362156Cytotoxicity against human A549 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID631732Antimicrobial activity against Cryptococcus neoformans ATCC 90113 by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID631731Antimicrobial activity against Candida albicans ATCC 90028 by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297525Antimicrobial activity against Fusarium solani at 30 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297549Antimicrobial activity against Fusarium proliferatum at 30 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297524Antimicrobial activity against Fusarium oxysporum at 30 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID362151Cytotoxicity against human LNcaP cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID379201Antifungal activity against Saccharomyces cerevisiae DSM 1333 at 5 ug/disk after 24 hrs by agar diffusion assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID297548Antimicrobial activity against Fusarium proliferatum at 30 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297527Cytotoxicity against human A549 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297543Antimicrobial activity against Cryptococcus neoformans ATCC 901132007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID1192635Cytotoxicity against mouse L5178Y cells by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Cytotoxic acyl amides from the soil fungus Gymnascella dankaliensis.
AID362158Cytotoxicity against human PANC1 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID297506Antimicrobial activity against Escherichia coli2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631208Cytotoxicity against human HCT15 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID362163Cytotoxicity against human HeLa-APL cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID631190Antimicrobial activity against Mycobacterium intracellular ATCC 23068 after 5 days by MABA assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID379200Antifungal activity against Cladosporium cucumerinum DSM 62122 at 5 ug/disk after 24 hrs by agar diffusion assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID362157Cytotoxicity against human K562 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID379195Cytotoxicity against mouse L1578Y cells after 24 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID297535Cytotoxicity against human SNB75 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID362154Cytotoxicity against human SKBR3 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID362152Cytotoxicity against human IGROV cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID362161Cytotoxicity against human doxorubicin resistant LoVo cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID297510Antimicrobial activity against Mycobacterium intracellular ATCC 230682007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631261Cytotoxicity against human PC3 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID379203Antibacterial activity against Escherichia coli DSM 10290 at 5 ug/disk after 24 hrs by agar diffusion assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID631252Cytotoxicity against human SKOV3 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297539Cytotoxicity against human PC3 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297532Cytotoxicity against human HCT15 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631245Cytotoxicity against human UACC257 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID612455Antiproliferative activity against mouse L5178Y cells after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.
AID297545Antimicrobial activity against Fusarium proliferatum at 0.3 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID1066617Cytotoxicity against mouse L5178Y cells assessed as growth inhibition by MTT assay2014Journal of natural products, Feb-28, Volume: 77, Issue:2
Cytotoxic and protein kinase inhibiting nakijiquinones and nakijiquinols from the sponge Dactylospongia metachromia.
AID297542Cytotoxicity against human HS578T cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631266Cytotoxicity against human Hs578T cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID631735Antimicrobial activity against Escherichia coli ATCC 35218 by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID631195Cytotoxicity against human RPMI8226 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297544Antimicrobial activity against Fusarium proliferatum at 0.3 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631206Cytotoxicity against human HCC2998 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297511Antimicrobial activity against Aspergillus fumigatus ATCC 909062007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297536Cytotoxicity against human UACC257 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297537Cytotoxicity against human SK-OV3 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297529Cytotoxicity against human RPMI8226 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297507Antimicrobial activity against Pseudomonas aeruginosa2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID469267Cytotoxicity against mouse L5178Y cells by MTT assay2009Journal of natural products, Sep, Volume: 72, Issue:9
Drimane sesquiterpenoids from the fungus Aspergillus ustus isolated from the marine sponge Suberites domuncula.
AID297528Cytotoxicity against human NCI-H322M cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297522Antimicrobial activity against Fusarium solani at 3 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID731496Cytotoxic activity against mouse L5178Y cells by MTT assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Aaptamine derivatives from the Indonesian sponge Aaptos suberitoides.
AID379198Cytotoxicity against rat PC12 cells after 24 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID362162Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID631216Cytotoxicity against human SNB75 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297554Antifungal activity against Fusarium proliferatum at 20 ug/mL after 3 days by fluorescence assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297521Antimicrobial activity against Fusarium solani at 3 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631733Antimicrobial activity against Aspergillus fumigatus ATCC 90906 by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297556Fungicidal activity against Fusarium oxysporum at 30 uM after 72 hrs by microtiter plate assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631734Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID362153Cytotoxicity against human IGROV-ET cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID362155Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID631202Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID362150Cytotoxicity against human DU145 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID297519Antimicrobial activity against Fusarium oxysporum at 3 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297551Fungicidal activity against Fusarium proliferatum at 30 uM after 72 hrs by microtiter plate assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297513Antibacterial activity against Mycobacterium tuberculosis H37Rv at 16 ug/mL by micro plate alamar blue assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID750903Cytotoxicity against mouse L5178Y cells by MTT assay2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Alkaloids and polyketides from Penicillium citrinum, an endophyte isolated from the Moroccan plant Ceratonia siliqua.
AID297512Antiparasitic activity against Leishmania donovani2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631210Cytotoxicity against human KM12 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID631191Antimicrobial activity against Fusarium sp. by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID631209Cytotoxicity against human HT-29 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297547Antimicrobial activity against Fusarium proliferatum at 3 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297509Antimicrobial activity against Candida albicans ATCC 900282007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID362160Cytotoxicity against human LoVo cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID297553Fungicidal activity against Fusarium solani at 30 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297518Antimicrobial activity against Fusarium solani at 0.3 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297523Antimicrobial activity against Fusarium oxysporum at 30 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297533Cytotoxicity against human HT29 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297515Antimicrobial activity against Fusarium oxysporum at 0.3 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID379199Antifungal activity against Cladosporium herbarum DSM 62121 at 5 ug/disk after 24 hrs by agar diffusion assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID297534Cytotoxicity against human KM12 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID631197Cytotoxicity against human A549 cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297517Antimicrobial activity against Fusarium solani at 0.3 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297516Antimicrobial activity against Fusarium oxysporum at 0.3 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297526Antimicrobial activity against Fusarium solani at 30 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID297508Antimicrobial activity against methicillin-resistant Staphylococcus aureus2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID362159Cytotoxicity against human HT29 cells after 48 hrs by SRB assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structure-activity relationship of kahalalide F synthetic analogues.
AID423617Cytotoxicity against mouse L5178Y cells by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Bioactive metabolites from the endophytic fungus Stemphylium globuliferum isolated from Mentha pulegium.
AID297520Antimicrobial activity against Fusarium oxysporum at 3 uM after 72 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID384276Growth inhibition of human PC3 cells2008Journal of natural products, May, Volume: 71, Issue:5
Kahalalides V-Y isolated from a Hawaiian collection of the sacoglossan mollusk Elysia rufescens.
AID384277Growth inhibition of human DU145 cells2008Journal of natural products, May, Volume: 71, Issue:5
Kahalalides V-Y isolated from a Hawaiian collection of the sacoglossan mollusk Elysia rufescens.
AID379197Cytotoxicity against rat H4IIE cells after 24 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID1182953Cytotoxicity against mouse L5178Y cells by MTT assay2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Trimeric anthracenes from the endophytic fungus Stemphylium globuliferum.
AID379202Antibacterial activity against Bacillus subtilis DSM 2109 at 5 ug/disk after 24 hrs by agar diffusion assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID631255Cytotoxicity against human ACHN cells by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297538Cytotoxicity against human ACHN cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID405780Cytotoxicity against mouse L5178Y cells by MTT assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Cytotoxic metabolites from the fungal endophyte Alternaria sp. and their subsequent detection in its host plant Polygonum senegalense.
AID631298Acute toxicity in iv dosed mouse assessed as mortality2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297514Antibacterial activity against Mycobacterium tuberculosis H37Rv by micro plate alamar blue assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID379194Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID297546Antimicrobial activity against Fusarium proliferatum at 3 uM after 48 hrs by microtiter assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
AID469269Cytotoxicity against human HeLa cells by MTT assay2009Journal of natural products, Sep, Volume: 72, Issue:9
Drimane sesquiterpenoids from the fungus Aspergillus ustus isolated from the marine sponge Suberites domuncula.
AID379196Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2006Journal of natural products, Nov, Volume: 69, Issue:11
Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
AID469268Cytotoxicity against rat PC12 cells by MTT assay2009Journal of natural products, Sep, Volume: 72, Issue:9
Drimane sesquiterpenoids from the fungus Aspergillus ustus isolated from the marine sponge Suberites domuncula.
AID631189Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by CLSI method2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
AID297531Cytotoxicity against human HCC2998 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.85)18.2507
2000's34 (62.96)29.6817
2010's18 (33.33)24.3611
2020's1 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (8.77%)5.53%
Reviews12 (21.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (70.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		3.5720amino-acid anion
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		210alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.4520aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
indibulin
indibulin: Tubulin Modulator/Antineoplastic Agent; structure in first source		2.0210
emodin
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.		2.0510trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
rofecoxib
[no description available]		2.0210butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		210glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.1810pyrrole;
secondary amine
captan
Captan: One of the phthalimide fungicides.. captan : A dicarboximide that is 3a,4,7,7a-tetrahydrophthalimide in which the hydrogen attached to the nitrogen is replaced by a trichloromethyl group. A non-systemic fungicide introduced in the 1950s, it is widely used for the control of fungal diseases in fruits, vegetables, and ornamental crops.		2.0310isoindoles;
organochlorine compound;
organosulfur compound;
phthalimide fungicide		antifungal agrochemical
thiazoles
[no description available]		3.18101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		7.0510copper group element atom;
elemental gold
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.4520taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
1,7-phenanthroline
[no description available]		3.1810phenanthroline
fascaplysine
fascaplysine: from tropic sea sponges		3.1810
altersolanol a
altersolanol A: isolated from fermentation product of fungus Alternaria porri(Ellis) Ciferri;RN given refers to (1R-(1alpha,2beta,3beta,4alpha))-isomer; structure given in first source		2.0510pentahydroxyanthraquinone
cremophor el
cremophor EL: solvent for Althesin & Propanidid implicated as possible cause of similar adverse effects polyethoxylated castor oil; RN given refers to cpd with unknown MF; see also records for cremophor & cremophor A		210
altertoxin i
altertoxin I: structure given in first source; isolated from Alternaria species; do not confuse with Anemonia sulcata toxin I which is also abbreviated ATX I		2.0410
ecteinascidin 743
[no description available]		5.3250acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
aaptamine
aaptamine: natural product from sea sponge Aaptos aaptos; structure given in first source; RN from CA Index Guide 1984		3.5920
lestaurtinib
[no description available]		3.1810indolocarbazole
macrosporin
macrosporin: isolated from fermentation product of fungus Alternaria porri (Ellis) Ciferri; structure given in first source		2.0510
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		2.0410biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
enzastaurin
[no description available]		3.1810indoles;
maleimides
ascididemin
ascididemin: can be viewed as a fused phenanthroline with quinoline; from the Mediterranean ascidian Cystodytes dellechiajei; structure in first source		3.1810
azoxystrobin
azoxystrobin: a methoxyacrylate analog; a strobilurin fungicide; structure given in first source. azoxystrobin : An aryloxypyrimidine having a 4,6-diphenoxypyrimidine skeleton in which one of the phenyl rings is cyano-substituted at C-2 and the other carries a 2-methoxy-1-(methoxycarbonyl)vinyl substituent, also at C-2. An inhibitor of mitochondrial respiration by blocking electron transfer between cytochromes b and c1, it is used widely as a fungicide in agriculture.		2.0310aryloxypyrimidine;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
methyl ester;
nitrile		antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
quinone outside inhibitor;
xenobiotic
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.4520antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
lutein
Lutein: A xanthophyll found in the major LIGHT-HARVESTING PROTEIN COMPLEXES of plants. Dietary lutein accumulates in the MACULA LUTEA.. xanthophyll : A subclass of carotenoids consisting of the oxygenated carotenes.		2.3110carotenolfood colouring;
plant metabolite
norlichexanthone
norlichexanthone: isolated from fungus P16; structure in first source. norlichexanthone : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3 and 6 and a methyl group at position 8. It has been isolated from Wardomyces anomalus.		2.0610polyphenol;
xanthones		antimalarial;
fungal metabolite
su 11248
[no description available]		2.0610monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
alternariol
alternariol: structure. alternariol : A benzochromenone that is 6H-benzo[c]chromen-6-one which is substituted by a methyl group at position 1 and by hydroxy groups at positions 3, 7, and 9. It is the most important mycotoxin produced by the black mould Alternaria species, which are the most common mycoflora infecting small grain cereals worldwide.		2.0410benzochromenone;
phenols		EC 3.1.1.8 (cholinesterase) inhibitor;
metabolite;
mycotoxin
alternariol monomethyl ether
djalonensone : A benzochromenone that is alternariol in which the hydroxy group at position 9 has been converted into the corresponding methyl ether. A natural product found in Chaetomium globosum as well as being one of the two most important compounds belonging to the group of Altenaria mycotoxins.		2.0410aromatic ether;
benzochromenone		antifungal agent;
fungal metabolite;
mycotoxin
cryptophycin 1
[no description available]		3.2110
soblidotin
soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R*(R*),2S*),2R*(1S*,2S*)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.		3.2510tetrapeptideantineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
altenusin
altenusin: structure given in first source. altenusin : A carboxybiphenyl that is [biphenyl]-2-carboxylic acid which is substituted by a hydroxy group at positions 3, 4' and 5', methoxy group at position 5 and a methyl group at position 2'. It is a a metabolite isolated from Alternaria and several other fungal species.		2.0410aromatic ether;
carboxybiphenyl;
catechols;
hydroxybiphenyls;
polyphenol		antifungal agent;
fungal metabolite
staurosporine
staurosporinium : Conjugate acid of staurosporine.		3.1810ammonium ion derivative
plitidepsin
plitidepsin: a cyclodepsipeptide isolated from Aplidium albicans; has a pyruvoyl-proline residue instead of the lactyl-proline residue found in the linear peptide moiety of didemnin B. plitidepsin : A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans.		5.6860didemninanticoronaviral agent;
antineoplastic agent;
marine metabolite
variolin b
variolin B: from Antartic sponge, Kirkpatrickia variolosa; structure in first source		3.1810
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		3.1810benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
elisidepsin
elisidepsin: antineoplastic; structure in first source. elisidepsin : A synthetic cyclodepsipeptide derived from a marine metabolite that exhibits antineoplastic properties.		4.0920cyclodepsipeptideantineoplastic agent
es-285
spisulosine: from marine organism, Spisula polynyma; structure in first source. 1-deoxysphinganine : A bioactive sphingoid, sphinganine, in which the terminal hydroxy group has been replaced by a hydrogen.		8.1310amino alcohol;
sphingoid		antineoplastic agent
halichondrin b
halichondrin B: from marine sponge Halichondria okadai; binds in the Vinca domain of tubulin		2.0510furopyran
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		2.0310nystatins
marizomib
marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source		3.1810beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide		antineoplastic agent;
proteasome inhibitor
myrocin a
myrocin A: secondary metabolite from the marine endophytic fungus Apiospora montagnei; structure in first source		2.0610tertiary alcoholmetabolite
liphagal
liphagal: selective inhibitor of PI3 kinase alpha isolated from the sponge akacoralliphaga; structure in first source. liphagal : A meroterpenoid isolated from the marine sponge Aka coralliphaga and has been shown to exhibit inhibitory activity against phosphatidylinositol-3-OH kinase.		3.1810aldehyde;
cyclic ether;
meroterpenoid;
organic heterotetracyclic compound;
polyphenol		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
metabolite
discodermolide
discodermolide: a lactone-bearing polyhydroxylated alkatetraene from the marine sponge Discodermia dissoluta; microtubule-stabilizing agent like taxol		3.5720
sphingosine kinase
[no description available]		3.1810
bryostatin 1
bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S*-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.		3.1810
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.110
ly 355703
cryptophycin 52: an antimitotic antitumor agent; structure in first source		3.2110
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		2.0110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0310cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
cephalostatin i
cephalostatin I: two steroid units are annulated to a 1,4-pyrazine ring; RN given for (3'R-(3'alpha(R*),4'alpha,4'abeta,6'balpha,8'abeta,11'aalpha,11'bbeta,13'alpha,13'aalpha,13'bbeta,14'beta,15'alpha(3*R*,5''S*),16'abeta,17'balpha,19'abeta,22'aalpha,22'bbeta,24'aR'*))-isomer; structure in first source		3.1810
ConditionIndicatedRelationship StrengthStudiesTrials
Animal Mammary Carcinoma
[description not available]		02.0310
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		02.0310
Benign Neoplasms
[description not available]		07.7592
Angiogenesis, Pathologic
[description not available]		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		07.7592
Germinoblastoma
[description not available]		02.1110
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.1110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.3110
Blood Pressure, High
[description not available]		03.0610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		03.0610
Acute Liver Injury, Drug-Induced
[description not available]		03.4711
Carcinoma, Non-Small Cell Lung
[description not available]		04.7721
Cancer of Lung
[description not available]		04.7721
Colorectal Cancer
[description not available]		03.4711
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		04.7721
Lung Neoplasms
Tumors or cancer of the LUNG.		04.7721
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		03.4711
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		03.4711
Allergic Contact Dermatitis
[description not available]		02.110
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		02.110
Cutaneous T-Cell Lymphoma
[description not available]		03.0310
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		03.0310
Metastase
[description not available]		03.0310
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		03.0310
Malignant Melanoma
[description not available]		08.4311
Cancer of Skin
[description not available]		03.4311
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		08.4311
Skin Neoplasms
Tumors or cancer of the SKIN.		03.4311
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.0110
Breast Cancer
[description not available]		07.0110
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.0110
Cancer of Prostate
[description not available]		03.8121
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		03.8121
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		07.0210
Hepatocellular Carcinoma
[description not available]		02.0210
Cancer of Liver
[description not available]		02.0210
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0210
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0210